AgingResearch.NewsJoin free

Lactobacillus johnsonii

Intervention

1 paper4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Ministry of Science and ICT, South Korea and 2 more
  • Animals1

Outcomes

4

Hepatic lipid accumulation

downin mice1

1 study

  1. Lactobacillus johnsonii decreases hepatic lipid accumulation in mice.

    “LJ3402 suppresses mitochondrial dysfunction and senescence of hepatocytes by stimulating the PGC-1α-SIRT1-p53 pathway, reducing age-related hepatic lipid accumulation.”

    Animalsliver

    Lactobacillus johnsonii JNU3402 Ameliorates Age-Related Liver Dysfunction Through Stimulating PGC-1α-Mediated SIRT1 Expression

    BioFactors (Oxford, England)1 Jan 2025

Cellular senescence

downin mice1

1 study

  1. Lactobacillus johnsonii decreases cellular senescence in mice.

    “limiting age-related mitochondrial dysfunction and hepatocyte senescence”

    Animalsliver

    Lactobacillus johnsonii JNU3402 Ameliorates Age-Related Liver Dysfunction Through Stimulating PGC-1α-Mediated SIRT1 Expression

    BioFactors (Oxford, England)1 Jan 2025

More on Cellular senescence

Metabolic dysfunction-associated steatotic liver disease

downin mice1

1 study

  1. Lactobacillus johnsonii decreases metabolic dysfunction-associated steatotic liver disease in mice.

    “contributing to the attenuation of metabolic dysfunction-associated steatotic liver disease (MASLD) progression.”

    Animalsliver

    Lactobacillus johnsonii JNU3402 Ameliorates Age-Related Liver Dysfunction Through Stimulating PGC-1α-Mediated SIRT1 Expression

    BioFactors (Oxford, England)1 Jan 2025

More on Metabolic dysfunction-associated steatotic liver disease

Hepatic dysfunction

downin mice1

1 study

  1. Lactobacillus johnsonii decreases hepatic dysfunction in mice.

    “LJ3402 administration reduces hepatic dysfunction in 24-month-old mice alongside the alleviation of general aging phenotypes.”

    Animalsliver

    Lactobacillus johnsonii JNU3402 Ameliorates Age-Related Liver Dysfunction Through Stimulating PGC-1α-Mediated SIRT1 Expression

    BioFactors (Oxford, England)1 Jan 2025

Latest

Related